Clovis Oncology Inc (CLVS.OQ)
26 Sep 2016
NEW YORK Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.
NEW YORK, Sept 26 Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.
BRIEF-Clovis Oncology -FDA has notified it is not currently planning to hold advisory committee meeting to discuss for Rucaparib
* FDA has notified co that FDA is not currently planning to hold advisory committee meeting to discuss NDA for Rucaparib Source text: [http://bit.ly/2c9EYtK] Further company coverage:
* Entered into first amendment to license agreement between Clovis and Pfizer, Inc.
* FDA accepts Clovis Oncology's new drug application for rucaparib for priority review for the treatment of advanced mutant BRCA ovarian cancer
* Clovis oncology announces q2 2016 operating results and corporate update
* Shares of rival Clovis Oncology also rise (Adds details; analyst comments)
* Clovis Oncology Inc files for mixed shelf of up to $200 million Source text: http://1.usa.gov/1XdI04i Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
* Nineteen patients (9%) discontinued treatment because of an adverse event.
* Clovis oncology announces q1 2016 operating results and corporate update
|Eisai Co., Ltd (4523.T)||¥6,467||+45.00|
|Pfizer Inc. (PFE.N)||$33.64||-0.62|
|AstraZeneca plc (AZN.L)||5,052.00p||-47.00|
|BioMarin Pharmaceutical Inc. (BMRN.OQ)||$95.87||--|
|TESARO Inc (TSRO.OQ)||$107.82||--|
|AbbVie Inc (ABBV.N)||$64.07||-0.91|
|Novartis AG (NOVN.S)||CHF77.65||-0.35|
|Johnson & Johnson (JNJ.N)||$117.78||-1.03|
|Eli Lilly and Co (LLY.N)||$79.52||-1.64|
|GlaxoSmithKline plc (GSK.L)||1,641.50p||+8.00|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (CLVS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Clovis Oncology Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.